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Abstract
The term Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus
infections (PANDAS) was coined by Swedo et al. in 1998 to describe a subset of childhood
obsessive-compulsive disorders (OCD) and tic disorders triggered by group-A beta-hemolytic
Streptococcus pyogenes infection. Like adult OCD, PANDAS is associated with basal ganglia
dysfunction. Other putative pathogenetic mechanisms of PANDAS include molecular mimicry and
autoimmune-mediated altered neuronal signaling, involving calcium-calmodulin dependent protein
(CaM) kinase II activity. Nonetheless the contrasting results from numerous studies provide no
consensus on whether PANDAS should be considered as a specific nosological entity or simply a
useful research framework. Herein we discuss available data that could provide insight into
pathophysiology of adult OCD, or might explain cases of treatment-resistance. We also review the
latest research findings on diagnostic and treatment.
Introduction
Several studies provide compelling evidence of cortico-
subcortical involvement in the pathogenesis of obsessive-
compulsive disorder (OCD) [1]. Data emerging from
morphological and functional neuroimaging studies sug-
gest specific alterations at the level of orbitofrontal-cau-
date-thalamic circuits [2,3]. Patients with adult-onset
OCD often have a history of ischemic stroke or traumatic
brain injury involving the basal ganglia [4-6]. Moreover,
indirect evidence of basal ganglia involvement in OCD
comes from observations that the symptoms of OCD
regress after surgery for cingulotomy and capsulotomy,
interventions that disconnect the frontal cortex from basal
ganglia [7,8].
Despite advances in the knowledge of the pathogenesis of
OCD, little is known about the causative mechanisms
underlying specific alterations. Observations of patients
with rheumatic fever who had Sydenham's chorea mani-
festing with classic OCD symptoms have suggested a pos-
sible etiological link between group A β-hemolytic
streptococcus (GABHS) infection in a subset of OCD
patients [9-11]. GABHS has also been implicated in the
development of Tourette syndrome [12-14] and autism in
children [15].
These clinical reports engendered considerable interest in
a possible streptococcal-triggered etiology for OCD. In
1998 the National Institute of Mental Health instituted a
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research group that sought to characterize a subgroup of
children with OCD and tic disorders (TD), namely "pedi-
atric autoimmune neuropsychiatric disorders associated
with streptococcal infections" (PANDAS) [16]. These
investigators outlined diagnostic criteria, studied several
candidate PANDAS patients and proposed a possible
pathophysiologic mechanism according to which a sus-
ceptible host might produce antibodies against GABHS
that cross-react with neuronal tissue [16]. This mecha-
nism resembles what happens in GABHS post-infection
sequelae glomerulonephritis and rheumatic fever. Evi-
dence suggesting a possible association between OCD and
GABHS infection also in adults, comes from three case
reports describing the abrupt onset of OCD due to GABHS
infection [17-19]. In all cases the infection and obsessive-
compulsive symptoms both promptly responded to anti-
biotics.
Recent evidence suggests that specific antibodies targeted
to the dominant epitope of GABHS (N-acetyl-beta-D-Glu-
cosamine) might influence neuronal signal transduction
thus causing alterations in behavior and movement con-
trol. Accordingly, sera from some patients with Syden-
ham's chorea [20] or PANDAS [21] contain antibodies
that induce calcium-calmodulin dependent protein
(CaM) kinase II activity.
Despite growing support for an association between
GABHS and OCD, the causal relationship between
GABHS infection and OCD, its pathophysiology, and its
possible clinical implication remain highly controversial.
In this paper we will review human studies aimed at veri-
fying the PANDAS construct. Our review focuses primarily
on the pathogenetic mechanisms underlying the develop-
ment of PANDAS. An important unanswered question is
whether some patients currently treated for OCD are actu-
ally undiagnosed PANDAS in childhood. Knowing more
about the pathogenesis of PANDAS might improve our
insight into pathogenetic mechanisms of treatment-resist-
ant OCD.
PANDAS: historical perspective
In 1994 Susan E. Swedo reported the case of a 9-year-old
girl with rheumatic chorea and OCD whose neuropsychi-
atric symptoms responded to plasma exchange [9]. In the
ensuing years a growing interest focused on the neuropsy-
chiatric features of rheumatic fever and reports described
patients with Sydenham's chorea who in up to 70% of
cases manifested obsessive-compulsive symptoms, appar-
ently indistinguishable from those of classic OCD [9,10].
The relationship between GABHS and Sydenham's chorea
has long been documented in the medical literature [22]:
streptococcal peptides stimulate specific lymphocyte
immune responses producing antibodies that might in
turn cross-react with various host epitopes, through the
mechanism known as molecular mimicry [23,24]. In
analogy to Sydenham's chorea, infections with GABHS
may trigger autoimmune responses that cause or exacer-
bate some cases of child-onset OCD, TD or Tourette syn-
drome [25].
The first systematic attempt to identify and define a noso-
logical entity characterized by pediatric OCD or TD, trig-
gered by an infection and with a supposed autoimmune
pathogenesis, dates back to 1995. In this year Allen and
co-workers described 4 patients in whom OCD or
Tourette syndrome manifested or worsened after GABHS
infection (two cases) and viral infection (two cases), and
responded to treatment with plasmapheresis, intravenous
immunoglobulin (IVIG) or immunosuppressive doses of
prednisone [25]. To summarize the essential features of
this subgroup of patients with OCD or TD, Allen et al.
coined the acronym PITANDs (pediatric infection-trig-
gered, autoimmune, neuropsychiatric disorders). As pos-
sible triggers of the neuropsychiatric manifestations they
originally included along with GABHS infection, viral or
other bacterial infections [25].
In a later study in 1998, Swedo et al. reappraised and
extended the diagnostic criteria for PITANDS, no longer
mentioned viral or other bacterial infections and hypoth-
esized the existence of PANDAS [16]. They proposed five
diagnostic criteria 1) the presence of OCD or a tic disorder
or both, 2) pediatric onset, 3) episodic course of symptom
severity with abrupt onset or dramatic symptom exacerba-
tions, 4) temporal association with GABHS infection 5)
and association with neurological abnormalities during
symptom exacerbations [16]. Whereas the PITANDs
hypothesis focused generally on a possible association
between "an antecedent or concomitant infection" and
neuropsychiatric manifestations, the diagnostic criteria
for PANDAS were restricted to GABHS infection.
In a systematic clinical evaluation of 50 children who met
the diagnostic criteria for PANDAS, Swedo and colleagues
found that these patients typically had a young age at ill-
ness onset, an abrupt onset of neuropsychiatric symptoms
and frequently manifested neuropsychiatric comorbidi-
ties (attention deficit hyperactivity disorder 40%, major
depressive disorder 36%, overanxious disorder 28%, sep-
aration anxiety disorder 20%, enuresis 12% [16]. GABHS
infection preceded 45 (31%) of 144 exacerbations of TD
or OCD. Moreover, the onset of behavioral symptoms
(irritability, emotional lability, tactile/sensory defensive-
ness, motor hyperactivity, deterioration in handwriting)
was typically associated with exacerbation of OCD or tics,
triggered by GABHS infections [16], also in patients who
had Sydenham's chorea [9].Clinical Practice and Epidemiology in Mental Health 2008, 4:13 http://www.cpementalhealth.com/content/4/1/13
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Subsequent studies investigating the PANDAS hypothesis
yielded controversial results. Some seemed to confirm the
association between GABHS infection and OCD or TD
exacerbations [26,27], whereas others failed [28,29]. Cir-
cumstantial evidence indicating PANDAS as an autoim-
mune disorder came also from the presence of anti-
neuronal (anti-brain, anti-basal ganglia) antibodies in
children with PANDAS [30-32] or children with Tourette
syndrome [33-35]. Again other studies failed to identify
significant differences into auto-antibody levels between
patients with PANDAS and controls [36-38]. The discrep-
ancies among the various researches presumably arise
partly from methodological problems: for example, the
use of rabbit neural antigens having low homology with
the human isoforms instead of human antigens [38].
Strong support for PANDAS as an immune-mediated dis-
order comes from the excellent response of children with
PANDAS to immunotherapies (plasma exchange and
IVIG) [39].
Prompted by a report that antibiotic prophylaxis dimin-
ished recurrences of rheumatic fever, some investigated a
possible analogous outcome in patients with PANDAS.
The first trial with oral penicillin was unsuccessful [40].
Another prospective longitudinal trial of azithromycin or
oral penicillin in 23 children with PANDAS showed that
antibiotic prophylaxis, with both molecules, effectively
decreased streptococcal infections and neuropsychiatric
symptoms exacerbations among children with PANDAS
[41].
Diagnostic issues
As well as stimulating considerable attention the PANDAS
hypothesis has generated controversy and skepticism. A
major criticism is although the currently proposed diag-
nostic criteria focus on the occurrence, onset, severity and
course of tic or obsessive compulsive symptoms they may
fail to distinguish PANDAS from other phenotypes of
OCD or tics, and to some degree even from Sydenham's
chorea [42,43]. A childhood onset of symptoms (second
criterion) may lack the specificity needed to distinguish
PANDAS from Tourette syndrome, because in up to 75%
of TD cases the manifestations begin during the prepuber-
tal period [44]. Moreover, in a series of 80 patients with
TD, 53% of the sample reported a sudden onset of illness
[45]. Furthermore, the specificity of a sudden and dra-
matic onset (third criterion) for the PANDAS subgroup of
OCD or TD or both has been questioned because some
reports describe cases of sudden-onset of adult OCD or
TD after GABHS [17,19,46,47]. Most children enrolled in
PANDAS studies manifested several neuropsychiatric
comorbidities especially attention deficit hyperactivity
disorder, anorexia nervosa, dystonia, trichotillomania,
major depressive disorder, or separation anxiety disorder
[16,30,31,41]. Whether these manifestations are inde-
pendent, secondary to the development of PANDAS or, at
least in some cases, could share a common pathogenetic
pathway is unclear. Obviously, the presence of neuropsy-
chiatric comorbidities limits the discriminating specificity
of the diagnostic criteria, but in childhood neuropsychiat-
ric disorders this is the rule rather than the exception. The
presence of neurological abnormalities (fourth criterion)
has been often referred to as the presence of choreiform
movements (reported in up to 95% of patients with PAN-
DAS in the acute phase), hence becoming a specific crite-
rion [16]. Those supporting the PANDAS hypothesis have
been excluding choreic movements as possible neurolog-
ical manifestation to avoid possible diagnostic overlap
between PANDAS and Sydenham's chorea, who often
present OCD or TD comorbidities [10,48]. Some authors
suggested that the PANDAS subgroup could represent an
attenuated form of Sydenham's chorea and that a dysfunc-
tion in the basal ganglia could be a common pathogenetic
pathway between choreiform movements and overt cho-
rea [42,49]. Subsequent studies nevertheless showed that
choreiform movements (elicited exclusively by a clinician
on a neurological examination disclosing stressed pos-
ture) could be reliably distinguished from choreatic
movements (rapid, involuntary, continuously increasing
arrhythmic movements that are present continuously and
increase during unrelated voluntary movements) [49,50].
Finally the temporal association (fifth criterion) between
GABHS infection, whose incidence in school-age children
is high, and the onset or the exacerbation of neuropsychi-
atric symptoms does not necessarily mean causality, the
question awaits an answer from further controlled pro-
spective studies. Streptococci were initially associated
with Kawasaki disease and Henoch-Schönlein purpura,
but controlled studies eliminated bacteria as a causal fac-
tor [42]. Streptococci are not the only infectious agents
implicated in Tourette syndrome, other pathogens puta-
tively involved include Borrelia burgdorferi and Myco-
plasma pneumoniae [51].
A recent study has shown that antibody test reactions for
Mycoplasma pneumoniae differ significantly in patients
with Tourette syndrome and healthy controls (59% vs.
3%) [51]. Even though most reports involve GABHS,
these data suggest that the autoimmune process underly-
ing post-infective autoimmune neuropsychiatric symp-
toms may be triggered not only by streptococci but also by
other infectious agents.
Physiopathology of GABHS infections
GAHBS is a Gram-positive, extracellular bacterium of
spherical to ovoid shape, and is one of the most frequent
human pathogens. Several clinical manifestations have
been associated with acute GABHS infections, including
pharyngitis (strep throat), scarlet fever, impetigo and cel-
lulitis [24]. GABHS produces several extracellular viru-Clinical Practice and Epidemiology in Mental Health 2008, 4:13 http://www.cpementalhealth.com/content/4/1/13
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lence factors including streptolysin S and O,
hyaluronidase, opacity factor, NADase and M-like pro-
teins. M protein is the major surface protein and occurs in
more than 100 antigenically distinct types, being the basis
for the serotyping of strains with specific antisera [24].
Bacterial cell wall M proteins have been found to mimic
several cardiac proteins and the group-specific carbohy-
drate of GABHS resembles the glycoprotein of heart
valves. Indirect evidence suggests that M6 and M19 pro-
teins may share common epitopes with brain structures
[52]. Group A streptococci also elaborate, to varying
degrees, a polysaccharide capsule composed of hyaluronic
acid. The description of new virulence factors, not present
in the earlier strains, together with a significant increase in
the incidence and severity of infections, has suggested that
GABHS genome has re-arranged over time. Evidence in
recent years suggests that new phage-encoded virulence
factors will be identified by sequencing the genomes of
additional GABHS strains [53].
An individual's vulnerability to infection-triggered
autoimmune disorders depends crucially on genetics.
Family-based studies support a genetic predisposition to
rheumatic fever [54]. Rheumatic fever is an inflammatory
disease that can involve heart, joints, skin and brain.
Sydenham's chorea is the most frequent neurological
manifestation of rheumatic fever and is characterized by
rapid, uncoordinated jerking movements affecting prima-
rily face, feet and hands. Rheumatic fever is believed to be
caused by antibody cross-reactivity. This cross-reactivity is
a Type II hypersensitivity reaction often referred to as
molecular mimicry [54]. Substantial evidence argues for
molecular mimicry also in Sydenham's chorea, and anti-
GABHS antibodies could cross-react with neuronal tissue
[54].
A pioneering study on children with Sydenham's chorea
found that 46.6% of sera from 30 patients reacted with
neuronal cytoplasm of human caudate and subthalamic
nuclei and the presence of anti-neuronal antibody was
associated with the severity and duration of clinical
attacks [55]. Several subsequent studies investigated the
presence of anti-neural or anti-brain antibodies in move-
ment disorders. Antineural antibodies directed against
caudate nuclei were found in 10 of 11 patients with
Sydenham's chorea [56]. In a later study, Church and col-
leagues found higher titers of anti-basal ganglia antibod-
ies in patients with acute Sydenham's chorea than in
convalescent patients [57].
Antineuronal autoantibodies
The presence of systemic anti-basal ganglia autoantibod-
ies has been proposed as possible evidence for an immu-
nological pathogenesis of a subset of OCD. The
modulation of intracellular signalling pathways by
autoantibodies has been described in myasthenia gravis
[58] (autoantibodies to the acetylcholine receptor block-
ing neuromuscular transmission) and Graves disease [59]
(autoantibodies against thyroid-stimulating hormone).
Nonetheless basal ganglia, like most CNS structures, are
relatively inaccessible to circulating antibodies owing to
the presence of the blood-brain barrier (BBB). Although
the mechanism by which circulating antibodies or
cytokines might gain access to the CNS is unknown, with
the exception of the circumventricular/lamina terminalis
region, where the BBB is absent [60], a variety of hypo-
thetic mechanisms exist. For example, circulating antibod-
ies could reach the CNS if an inflammation of the
meninges causes a local BBB breakdown. Cytokines, prob-
ably crossing the BBB at circumventricular organs, can
trigger an immune activation on the CNS side of the BBB.
Moreover, peripheral B cells that are cross-reactive to a
CNS epitope may cause intrathecal production of anti-
bodies [61].
To test the specificity of the association between anti-
brain antibodies and the neuropsychiatric symptoms in
PANDAS, Pavone and colleagues compared a group of
PANDAS children with patients with uncomplicated
(without neuropsychiatric manifestations) GABHS active
infection [30]. They found a far higher incidence of anti-
brain antibodies in serum from children with PANDAS
than in those with active GABHS infection (64% vs. 9%)
suggesting that the presence of anti-brain antibodies
could not be accounted for by GABHS infection alone
[30]. Further support for an immune-mediated pathogen-
esis of OCD in a subset of patients came from a study by
Dale et al. that compared anti-basal ganglia antibody
(ABGA) titers among patients with OCD and three control
groups (neurological patients, uncomplicated GABHS
infection, autoimmune disorders) and found significantly
higher antibody expression in the OCD group (42% vs.
4%, 2%, and 10% in the three control groups) [31]. In the
same study the authors found that the mean CY-BOCS
score in the antibody-negative patients was higher than in
the antibody-positive patients, and the latter had lower
obsessions of hoarding/saving [31]. Others nevertheless
also found anti-brain antibodies in healthy controls
[14,33]. Two successive studies found no significant dif-
ferences for ABGA immunoreactivity between patients
with PANDAS vs. controls [36] and between children who
met PANDAS criteria and two control groups (healthy
controls and patients with TD) [37]. These discrepancies
in autoantibody findings could reflect the methods used
for antibody detection: enzyme-linked immunosorbent
assay (ELISA) and western blotting which can alter the
conformation of the antigens and could therefore affect
antibody-antigen interactions [31].Clinical Practice and Epidemiology in Mental Health 2008, 4:13 http://www.cpementalhealth.com/content/4/1/13
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Despite existing evidence of brain-specific antibody reac-
tivity, and the isolation of antibodies against basal ganglia
evoked by streptococcal cell wall, the mechanism by
which molecular mimicry results in a behavioral or move-
ment alteration is still unclear. Recent work by Kirvan and
colleagues suggests that the pathogenesis of PANDAS and
Sydenham's chorea might involve immune-mediated
altered neuronal signaling [20,21]. These investigators
first demonstrated that monoclonal antibodies derived
from patients with acute Sydenham's chorea and targeted
to N-acetyl-beta-D-glucosamine (GlcNAc), the dominant
epitope of GABHS, reacted with human lysoganglioside
GM1. This lysoganglioside influences neuronal signal
transduction [62]. Moreover the autoantibody 24.3.1,
from sera of patients with acute Sydenham's chorea
induced CaM kinase II activity, whereas serum obtained
from convalescent patients did not [20]. A recent work
from the same group reported that antibodies which react
with lysoganglioside GM1 and induce CaM kinase II acti-
vation in neuronal cells are present in PANDAS [21].
Using competitive-inhibition ELISA Kirvan et al. found
that soluble lysoganglioside GM1 inhibited 73% of sera
from patients with PANDAS binding to GlcNAc (conju-
gated to bovine serum albumin) but only 23% of sera
from controls (OCD, tic disorders, attention deficit hyper-
activity disorder, patients not meeting PANDAS criteria)
[21]. Moreover, using human neuroblastoma cell cul-
tures, they showed that PANDAS sera specifically induced
antibody-mediated activation of CaM kinase II (75% per-
cent of acute PANDAS sera), the degree of activation being
superior to non-PANDAS sera and inferior to chorea sera.
PANDAS sera depleted of IgG did not activate CaM kinase
II. Notably the degree of activation of CaM kinase II was
highest in PANDAS patients with isolated tics.
Current data emerging for patients with chorea, PANDAS
and OCD seem to suggest that CaM kinase II could be an
intracellular mediator of behavioral and motor manifesta-
tions in some neuropsychiatric disorders. Along a contin-
uum of activation from low levels (e.g. non-PANDAS
OCD) to extremely high levels (rheumatic chorea), CaM
kinase II activity seems to be associated in non-PANDAS
OCD with simple neuropsychiatric manifestations and in
rheumatic chorea with frank motor alterations. No studies
have yet shown whether the physiological systems activat-
ing this signal cascade interact with possible disease-
related (autoimmune ?) triggers. If they do, these interac-
tions could be a new target for possible pharmacological
approaches in disorders such as OCD and choreiform dis-
orders.
Peripheral markers
The research for a possible susceptibility marker for PAN-
DAS mostly focused on identifying peripheral markers.
Among proposed peripheral markers of PANDAS suscep-
tibility is monoclonal antibody directed against a non-
HLA B-cell marker known as D8/17. This antibody is an
IgM first isolated from fusions of spleen cells from mice
that had been repeatedly immunized with human B-cells
from patients with confirmed rheumatic fever [63,64].
In a study investigating D8/17 in PANDAS, Swedo and
colleagues compared 27 children who met the diagnostic
criteria with 9 patients with Sydenham's chorea and 24
healthy controls, and found a significantly higher percent-
age of B cells that bind D8/17 monoclonal antibody in
children with both diseases than in controls (89% in
Sydenham's chorea, 85% in PANDAS, 17% in controls)
[65]. Another study of patients with child-onset OCD or
Tourette disorder found 100% positive reactions for D8/
17 in patients compared with 5% in the control group
[13]. Subsequent studies investigated D8/17 positive B-
cells in obsessive-compulsive spectrum disorders, as well
as in other neuropsychiatric disorders. High percentages
of B-cells expressing D8/17 were found in patients with
autism (78%) [15], anorexia nervosa (100%–81%)
[66,67], adult OCD (59%–92%) [68,69], tics (61%) [70]
and trichotillomania (59%) [68]. Recent studies that used
more accurate methods (flow cytometry) nevertheless
failed to replicate these results [71,72]. This discrepancy
may be due, at least in part, to the difference in the meth-
ods used in these studies, but also to the molecular char-
acteristics of the antibody. The antibody that binds to D8/
17 is an IgM, known to be relatively unstable and difficult
to purify.
Preliminary evidence suggests that D8/17 antigen immu-
noreactivity may reflect different psychopathological
characteristics among patients with obsessive-compulsive
spectrum. In a study on repetitive behaviors in autism
Hollander and colleagues investigated the presence of D8/
17 antigen in a sample of 18 children with autism. They
found that the D8/17-positive patients had significantly
higher mean children Yale-Brown obsessive compulsive
scale (CY-BOCS) compulsion scores than the D8/17-neg-
ative patients [15]. These results suggest that psychopath-
ological characteristics could differ in the various clinical
subgroups of patients with OCD according to the under-
lying pathogenetic mechanisms.
Neuroimaging
In recent years, evidence arising from morphological and
functional neuroimaging studies have linked OCD with
dysfunction in frontal-subcortical circuits. Strong evi-
dence exists of orbitofrontal cortex involvement but other
areas implicated in the pathogenesis of OCD include the
anterior cingulate gyrus, amygdala, insula, thalamus,
striatum, lateral frontal and temporal cortices [1-3]. Sev-
eral studies with positron emission tomography (PET)
reported increased glucose metabolism in the orbitofron-Clinical Practice and Epidemiology in Mental Health 2008, 4:13 http://www.cpementalhealth.com/content/4/1/13
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tal cortex, caudate, thalamus, prefrontal cortex and ante-
rior cingulate among patients with OCD [73-75]. Current
knowledge on the pathophysiology of OCD, despite sug-
gesting an involvement of discrete brain regions, is far
from concluding that these abnormalities are the cause of
OCD or just an epiphenomenon [2].
In 1996 Giedd et al. first described an association between
abrupt exacerbation of OCD symptoms after GABHS
infection and an enlargement of basal ganglia [76]. Rela-
tively few imaging studies have investigated CNS altera-
tions in SC, most studies found no pathological changes
on MRI. An MRI study of 24 children with SC, however,
found volumetric abnormalities in caudate, putamen and
globus pallidus [77]. Another study in a patient with
Sydenham's chorea detected striatal abnormalities
(increased signal intensity on T2-weighted images involv-
ing the putamen, globus pallidus, and the head of the cau-
date nucleus bilaterally) that reversed after recovery [78].
A subsequent longitudinal study with MRI compared 34
patients who met PANDAS criteria with 82 healthy con-
trols and found a significant enlargement of caudate,
putamen and globus pallidus in the patients [79]. Inter-
estingly, immunomodulatory treatment (plasma
exchange and IVIG) normalized this difference, suggest-
ing that basal ganglia abnormalities are reversible. The
same study found no correlation between symptom sever-
ity and basal ganglia volume [79].
Further longitudinal studies monitoring the CNS changes
such as autoimmune vasculitis and edema and OCD
symptoms that are supposed to follow GABHS infection
are needed to assess a possible causal role and the involve-
ment of specific CNS regions [80].
Therapeutic strategies
The neurobiological mechanisms underlying the patho-
physiology of OCD remain an intense area of research.
One of the most accepted theories supports an alteration
of serotonergic brain pathways, mainly because serotonin
reuptake inhibitors achieve better clinical efficacy than
other pharmacotherapeutic agents [81]. Double-blind,
placebo-controlled trials have shown the efficacy of clo-
mipramine and selective serotonin reuptake inhibitors
(SSRI) in the treatment of adult OCD [81]. Although
fewer, but consistent observations, suggest that clomi-
pramine and SSRI may be equally effective in the treat-
ment of childhood OCD, only clomipramine,
fluvoxamine and sertraline have been approved by the
FDA for child and adolescent OCD.
Several lines of evidence indicate that an optimal treat-
ment for OCD is combined pharmacotherapy and cogni-
tive behavioral therapy (CBT) [82]. Despite the advances
in pharmacological and psychotherapeutic approaches,
up to 40–60% of treated patients are still non-responders
or their response is unsatisfactory [83].
Some reports suggest that OCD or tics manifesting in
patients with PANDAS respond to serotonergic drugs and
combined therapy [84]. CBT and serotonergic drugs have
proven efficacy, whether or not the symptomatology is
triggered by a GABHS infection. Even in the PANDAS sub-
group many patients have an unsatisfactory response. The
true percentage of non-responders remains difficult to
define but probably approaches that in the non-PANDAS
subgroup.
When standard treatments fail and symptoms are severe
and disabling, Swedo and colleagues proposed immu-
nomodulatory interventions, tailored to the presumed
pathophysiology [84]. In a longitudinal double-blind pla-
cebo-controlled trial of 29 children with PANDAS, plasma
exchange, IVIG or sham IVIG proved better than placebo
in reducing OCD symptoms at 1-month follow-up (58%
improvement with plasma exchange, 45% with IVIG) and
tics (49% improvement with plasma exchange, 19% with
IVIG) as measured by CY-BOCS and Tourette syndrome
unified rating scale [39]. The improvements remained sta-
ble at 1 year follow-up, and were all statistically significant
(p < 0.05) with the exception of tics in the group treated
with IVIG. Whereas standard therapies (SSRI, cognitive
behavioral therapy) have proved efficacious in the PAN-
DAS subset of OCD and TD, immunotherapies were inef-
fective in children with resistant OCD without a history of
GABHS infection [85], suggesting that immunotherapy is
specific for PANDAS thus supporting the presumed
pathophysiology.
In a prospective longitudinal study 12 children who met
the diagnostic criteria for PANDAS, were treated with pen-
icillin or amoxicillin (5 patients), amoxicillin and clavu-
lanate (1 patient), or cephalosporin (6 patients) during
acute exacerbation of neuropsychiatric symptoms. In all
patients antibiotic therapy effectively resolved OCD, the
anxiety symptoms and tics within on average 14 days [26].
Penicillin prophylaxis has proven effective in preventing
recurrences of rheumatic fever, and the American Heart
Association recommend the use of oral penicillin 250 mg
twice a day for prevention [86]. Because of the hypothe-
sized pathophysiologic similarities between Sydenham's
chorea and PANDAS some have argued that penicillin
prophylaxis would also reduce neuropsychiatric exacerba-
tions in children with PANDAS. In the first controlled trial
on antibiotic prophylaxis for PANDAS, 37 children who
had been previously diagnosed as PANDAS, were rand-
omized to 4 months of penicillin V (twice daily oral 250
mg) followed by 4 months of placebo, or placebo fol-
lowed by penicillin. In this study oral penicillin failed to
provide adequate prophylaxis for GABHS and subse-Clinical Practice and Epidemiology in Mental Health 2008, 4:13 http://www.cpementalhealth.com/content/4/1/13
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quently for neuropsychiatric symptoms exacerbations
[40]. In a subsequent randomized trial Snider and col-
leagues tried to determine whether the negative results
from Garvey were due to inefficacious prophylaxis against
GABHS infection, and not to a lack of association between
GABHS infection and neuropsychiatric symptoms. The
study compared penicillin, considered as an "active pla-
cebo", with azithromycin, a drug that had proved effica-
cious against GABHS infections. In contrast to previous
studies, penicillin and azithromycin both effectively
decreased GABHS infections and neuropsychiatric exacer-
bations. The authors therefore concluded that antibiotic
prophylaxis may be useful in the management of children
with PANDAS [41].
Others later pointed out that the study had several limita-
tions: the small sample size, the use of an "active placebo"
and the retrospective methodology used to collect clinical
data (symptoms severity, previous GABHS infections)
regarding the year before patients were included in the
study [87,88]. More important, many patients had neu-
ropsychiatric comorbidities (as in all PANDAS studies)
and the study design failed to consider concomitant phar-
macological treatments as possible sources of confound-
ing. Current knowledge therefore seems insufficient to
support routine antibiotic prophylaxis for the symptoms
of PANDAS.
Conclusion
Despite the encouraging results from recent studies that
tested a possible autoimmune pathogenesis of PANDAS
also at an intracellular level, and found in CaM kinase II a
possible mediator of neuropsychiatric symptoms in this
subset of OCD or TD patients, the validity of this nosolo-
gic entity is still questioned. The presence of anti-brain
antibodies in a subset of patients with OCD, the promis-
ing results from immunomodulatory treatment in PAN-
DAS and the possible association between some upper
respiratory infections and the sudden onset of OCD, sug-
gest a supportive role for immune triggers in some OCD
subtypes. A research area that deserves further investiga-
tion regards the possible differences in the psychopatho-
logical characteristics of autoimmune-induced and non-
autoimmune-induced OCD. Our findings in this review
apart from confirming PANDAS as a distinct clinical
entity, suggest that PANDAS is a useful research field that
could open new insights into the pathogenesis of OCD,
even in adults.
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